The Latest News in the Peptide World

March 2024

01. Orbis Medicines Emerges with €26M Funding for Oral Peptide Therapies

Orbis Medicines, launching with a €26M seed round from Novo Holdings and Forbion, aims to revolutionize peptide-based therapeutics. Focusing on macrocyclic peptides for improved oral bioavailability, the startup leverages a novel technology platform enabling rapid, scalable compound production. This advancement could transform treatments for conditions currently addressed by biologics, offering patient-friendly oral dosing options and potentially overcoming challenges of poor gastrointestinal absorption and the requirement for cold chain logistics.


02. GLP-1 Drugs Projected to Stimulate Economic Growth, Says Goldman Sachs

Goldman Sachs Research indicates that groundbreaking GLP-1 obesity drugs and other healthcare innovations could significantly propel US GDP growth. These medical advances, notably in weight management, AI-driven drug discovery, genomic, and regenerative medicine, are poised to improve national economic health by enhancing workforce productivity and participation through better health outcomes and extended lifespans.


03. WuXi AppTec's Uncertain Future Amid Escalating US-China Biopharma Tensions

WuXi AppTec's significance in the global biopharma sector is under threat from US-China tensions, notably through the proposed BIOSECURE Act. Companies like Eli Lilly and Structure Therapeutics, reliant on WuXi for essential drug development and manufacturing services, face risks of operational disruptions. The Act could prevent firms using WuXi's services from securing government contracts, intensifying the search for alternatives and underscoring the geopolitical intricacies affecting biopharma collaborations.


04. Novo Nordisk Advances Green Chemistry in Peptide Synthesis

Novo Nordisk's green initiative in peptide synthesis integrates Oxyma for spectrophotometric monitoring, significantly lowering the environmental impact by reducing toxic solvent usage and optimizing the manufacturing process. This approach not only aims at sustainability but also prioritizes efficiency and safety in pharmaceutical production, marking a substantial advancement towards environmentally responsible peptide manufacturing practices.


05. CordenPharma Boosts Early Clinical Peptide Manufacturing Capabilities

CordenPharma is set to enhance its peptide API manufacturing with new GMP capacities at its Frankfurt facility, targeting early clinical phase requirements for pharma and biotech clients. Slated for full operation by 2Q24, the expansion includes 1000 m² of space with state-of-the-art synthesis and quality control labs, aiming for seamless transfer to late-phase manufacturing. This move complements an integrated service for peptide-drug substance and injectable drug products, streamlining IND/IMPD filings and the initiation of First In-Human clinical trials.


06. Innovating Keap1 Inhibition: Designing Cyclic Peptides via Computational Prediction

Researchers developed a computational method using all-atom, explicit-solvent molecular dynamics simulations to predict the structural ensembles of cyclic peptides, aiming to inhibit the Nrf2–Keap1 interaction, a crucial pathway in cellular response to oxidative stress. By correlating simulation predictions with experimental data, this study highlights a significant advancement in designing cyclic peptides as selective inhibitors, offering potential therapeutic strategies for cancer and inflammatory diseases through targeted protein–protein interaction disruption.


07. Targeting Disease Through Synthetic Peptides: A Focus on Nucleic Acids

The article delves into the development and application of synthetic peptides for the targeted manipulation of disease-related nucleic acids, including DNA and RNA. It highlights the therapeutic potential of peptides in interacting with specific nucleic acid structures, such as double-stranded DNA, regulatory G-quadruplexes, and various RNA forms, to modulate gene expression linked to diseases. This comprehensive review showcases the progress in peptide-based strategies to address challenging molecular targets, underscoring their significance in advancing therapeutic interventions.


08. Revolutionizing Antioxidant Peptide Design with Machine Learning and DFT

A groundbreaking study published in Scientific Reports introduces a novel method combining machine learning and density functional theory (DFT) to design antioxidant peptides. This approach accurately predicts peptides with high antioxidant capacity, identifying twelve peptides for synthesis. The study verifies their effectiveness through biological assays and explores their potential interaction with Keap1 protein, highlighting the power of computational tools in advancing antioxidant peptide research and their therapeutic applications.


09. Novel Temperature-Sensitive Fibrils for Drug Delivery by UNC and Emory Researchers

Scientists have developed synthetic amyloid peptides that could revolutionize drug delivery by forming fibrils whose twist direction can be thermally controlled. This innovative approach, utilizing temperature-sensitive fibrils for targeted drug release, holds promise for enhancing the effectiveness of treatments like chemotherapy and could provide insights into Alzheimer's disease by potentially reversing amyloid plaque formation. This breakthrough paves the way for new, more efficient drug delivery methods and therapeutic strategies.


10. Curve Therapeutics Secures Pfizer Support with £40.5M for Peptide Drugs

UK-based Curve Therapeutics has raised £40.5 million in Series A funding, led by Pfizer Ventures, to propel its small cyclic peptide-based discovery platform. The investment aims to advance two preclinical programs into a Phase I oncology trial by 2026, focusing on novel treatments targeting hypoxia-inducible factor isotopes and ATIC enzyme dimerization, showing promise against a range of tumors and certain cancers.



Get the top 10 highlights monthly in your inbox

About Us

CSBio is a leading peptide and instrumentation manufacturing company located in Silicon Valley, California.

CSBio provides nonGMP and cGMP peptides, peptide APIs, research scale peptide synthesizers, commerical scale peptide synthesizers, DNA/RNA oligonucleotide synthesizers, and preparative HPLC purification equipment.

Peptide Contact

20 Kelly Court
Menlo Park, CA 94025


Instrumentation Contact

915 Linda Vista Ave
Mountain View, CA, 94043